Rubius® is pioneering the creation of a new class of medicines to address a wide array of indications, with leading applications in the following areas.
- ENZYME REPLACEMENT THERAPY
- AUTOIMMUNE DISEASE AND TOLERANCE INDUCTION
Our lead programs are targeting diseases with no acceptable treatment options. Immuno-privileged presentation of our therapeutics increases efficacy, while the long half-life improves compliance and convenience.
Clinical trials are generally short and biomarkers can be used as a surrogate for efficacy and approval.
We can target, starve, penetrate and destroy tumors. We have demonstrated extraordinary immunomodulation and have been able to show that co-expressing two different moieties on a single cell generates a synergistic response.
We are building a combinatorial portfolio of binding, stimulation, starvation and killing modalities in a range of hematological and solid tumors.
Autoimmune disease and beyond
Our RCT™ constructs enable precise targeting of specific components of the immune system. We are leveraging our B-cell and T-cell work in oncology to build similar and mirror image constructs in autoimmune diseases. RCT constructs have been shown to induce dramatic antigen-specific tolerance, and thus, functionally cure a range of diseases.
Our in vivo functional rescue and survival data generated to date in a multiple sclerosis model is unprecedented.